Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 2, 2008 Michael P. Cecil	Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite.
The Motley Fool January 15, 2008 Brian Orelli	No Enhance-ment From Zetia Merck and Schering report bad news, but how much will it affect sales? Investors, take note.
The Motley Fool November 22, 2010 Brian Orelli	Let's Call It a Partial Victory Merck's Vytorin works better than a placebo. Unfortunately, it may be too little and too late to do anything about the sales cut that Vytorin has taken over the past few years.
The Motley Fool December 12, 2007 Brian Orelli	Congress Calls Out Merck and Schering-Plough The House of Representatives wants to know what's taking these pharmaceutical companies so long to release trial data from their ENHANCE clinical trial.
The Motley Fool December 23, 2009 Brian Orelli	Cancer Isn't Merck's Biggest Problem There's still hope for Merck's Vytorin, but investors will have to wait.
The Motley Fool January 9, 2009 Brian Orelli	Thanks for Nothing, FDA The Food and Drug Administration says there's still enough evidence that Merck and Schering-Plough's Vytorin works to warrant keeping patients on the drug.
The Motley Fool November 16, 2009 Brian Orelli	Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference.
The Motley Fool March 27, 2008 Brian Orelli	I Heart the ACC What can investors expect from this weekend's blood-pumping American College of Cardiology scientific meeting?
The Motley Fool February 4, 2009 Brian Orelli	The Tale of 2 Drugmakers Merck and Schering-Plough typically release earnings on the same day because they share sales of cholesterol drugs Vytorin and Zetia, but the drugmakers are far from the same.
The Motley Fool December 1, 2009 Robert Steyer	Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones.
The Motley Fool March 31, 2008 Brian Orelli	No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating.
The Motley Fool December 4, 2006 Michael P. Cecil	Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy?
The Motley Fool May 27, 2011 Brian Orelli	AIM-HIGH? These Drugmakers Better Duck. A government study on cholesterol drugs hurts Abbott and Merck.
BusinessWeek July 26, 2004 Amy Barrett	Hooked On The Cash From Cholesterol Cholesterol-lowering drugs are massive moneyspinners. But can big pharmaceutical companies sidestep expiring patents?
The Motley Fool September 24, 2010 Brian Orelli	Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year.
The Motley Fool July 22, 2008 Brian Orelli	Drug Duo SEAS Disappointment -- Again After numerous disappointments this year, Merck and Schering-Plough continue their string of bad luck.
Chemistry World May 2008 Derek Lowe	In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is.
Pharmaceutical Executive February 1, 2009 Walter Armstrong	Brand of the Year: Crestor For aiming to be a game-changer in cardiovascular disease, we recognize comeback kid Crestor as the year's No. 1. Plus three fine finalists.
Chemistry World February 19, 2013 Andrew Turley	Merck resolves Vytorin case for $688m Merck & Co has agreed to pay $688 million to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin).
The Motley Fool April 29, 2008 Brian Orelli	Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA.
The Motley Fool March 15, 2010 Brian Orelli	Clinical Outcomes? Who Needs 'Em. Abbott's TriCor looks good on lab tests, but that's about all.
BusinessWeek May 27, 2010 Michelle Cortez	Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug.
BusinessWeek March 11, 2010 Ellen Gibson	The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL.
The Motley Fool July 21, 2004 Brian Gorman	Will Cholesterol Drug Pack a Punch? Merck's and Schering-Plough's new combination may receive a lukewarm welcome. In the near term, investors will probably cheer both companies, but in the long run, the companies will be better off it they can come up with something totally original.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool May 22, 2008 Brian Orelli	Merck Can't Achieve Anything The pharmaceutical cancels a troubled clinical trial.
The Motley Fool December 30, 2003 Arash Mostaghimi	Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool December 23, 2003 Arash Mostaghimi	The Cholesterol Wars Who will win the fight to save your arteries? Fortunately for our corpulent country, pharmaceutical companies want to unclog our arteries -- and lighten our wallets. But which pharma stock will add to most girth to a portfolio?
The Motley Fool April 18, 2011 Brian Orelli	Up 95%! No Anchor Holding Amarin Down The second phase 3 trial of AMR101 deemed a success.
The Motley Fool November 18, 2009 Brian Orelli	Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data.
The Motley Fool November 15, 2011 Brian Orelli	Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck.
The Motley Fool September 2, 2008 Brian Orelli	Cardiologists Hate Vytorin Cardiologists seem cynical about the full presentation of Merck's and Schering-Plough's SEAS data at the European Society of Cardiology.
Chemistry World August 27, 2015 Phillip Broadwith	Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases.
The Motley Fool October 5, 2007 Brian Orelli	Merck's Next Blockbuster? Merck's cholesterol drug comes back from phase 2 testing with no side effects. Investors, take note.
The Motley Fool April 2, 2008 Brian Lawler	Bad Timing for AstraZeneca's Good Data AstraZeneca quietly reports a successful clinical study for its cholesterol-lowering lead drug.
BusinessWeek April 19, 2004 Catherine Arnst	Cholesterol: How Low Should It Be? New studies say as low as possible, but drugs aren't for everybody
The Motley Fool November 10, 2008 Brian Orelli	Drug Fuels an Idling Rocket Ship AstraZeneca needs another FDA approval to really take advantage of its cholesterol drug's success.
BusinessWeek November 22, 2004 Barrett & Carey	Wondering About A Wonder Drug While the benefits of statins, sold under names such as Lipitor and Zocor, are well established, some doctors argue that their side effects have not received adequate scrutiny.
The Motley Fool March 14, 2006 Brian Gorman	AstraZeneca's Heartening News A new study shows cholesterol drug Crestor's further potential. Will it help sales?
The Motley Fool March 30, 2009 Brian Orelli	To the Moon, Crestor? A few months ago, AstraZeneca released initial data showing how its cholesterol-lowering drug, Crestor, reduced the risk of heart attacks, strokes, and other heart-related issues by 44% in patients. Now it's back with more.
The Motley Fool August 30, 2007 Brian Orelli	Merck Tries to Stop the Flushing The FDA will review the pharma's new cholesterol drug. The biggest worry with getting CORDAPTIVE approved is probably not with its effectiveness, but with safety. Investors, take note.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool August 24, 2011 Brian Orelli	Can Roche and Merck Succeed Where Pfizer Failed? CETP inhibitors are lucrative but risky.
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
The Motley Fool September 7, 2007 Brian Orelli	Fighting the Generics Next Door Pfizer tries to stop patients from switching from it's patented Lipitor to generic Zocor by doing an observational study of patients on both medications.
The Motley Fool December 16, 2008 Brian Orelli	Doubling Up on Triple Lipid Drugs The Food and Drug Administration gave Abbott Lab's TriLipix the thumbs-up, approving it for use by itself or with statins.
The Motley Fool April 24, 2008 Brian Orelli	Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
The Motley Fool February 14, 2008 Brian Orelli	A Lovey-Dovey Duo Drug companies Schering-Plough and Merck hook up to market a 'hot, hot, hot!' product.
The Motley Fool December 4, 2008 Brian Orelli	Pfizer Blows Statin Smoke Pfizer presents some mildly persuasive numbers to try to win back customers for Lipitor.